Informative $ACOG CEO interview Found a great interview with the CEO of Alpha Cognition Inc. ( $ACOG $ACOG.v $ACOGF) from last month - super informative regarding the upcoming trial, as well as their additional pipeline projects.
ALPHA-1062 compound working towards approval for mild to moderate Alzheimer's
- Unique to competitors by focusing on the treatment of the symptoms that patients suffer from, rather than focusing on "stopping the disease" like other competitors are trying to do
- Treatment is for first-line therapy to ameliorate the symptoms
- Pivotal trial in Q4 was approved by the FDA; Will be completed in Q1 of 2022
Three additional pipeline programs
- Path to approval for moderate to severe Alzheimers with opportunity to compete from diagnosis to end of life
- Early stage mild traumatic brain injury
- Early stage gene therapy program for ALS also starting in Q4 of 2021 with results expected in Q1 of 2022